Results 41 to 50 of about 10,060 (149)

Blockage of interleukin-1β with canakinumab in patients with Covid-19

Scientific Reports, 2020
There is the urgent need to study the effects of immunomodulating agents as therapy for Covid-19. An observational, cohort, prospective study with 30 days of observation was carried out to assess clinical outcomes in 88 patients hospitalized for Covid-19
Lorenza Landi, Claudia Ravaglia, Emanuele Russo, Pierluigi Cataleta, Maurizio Fusari, Andrea Boschi, Diana Giannarelli, Francesca Facondini, Ilaria Valentini, Ilaria Panzini, Luigi Lazzari-Agli, Paolo Bassi, Elisa Marchionni, Rossella Romagnoli, Raffaella De Giovanni, Marina Assirelli, Federica Baldazzi, Fabio Pieraccini, Giovanna Rametta, Lucia Rossi, Luca Santini, Ivana Valenti, Federico Cappuzzo   +22 more
doaj   +1 more source

Case report on the use of canakinumab for treatment of recurrent fevers and proteinuria in refractory systemic lupus erythematosus

Therapeutic Advances in Rare Disease, 2023
Systemic lupus erythematosus (SLE) is a chronic multiorgan autoimmune disease with a wide range of clinical manifestations and a characteristic renal involvement leading to proteinuria.
Kimia Yavari, Joseph Grisanti
doaj   +1 more source

Off-label use of canakinumab in pediatric rheumatology and rare diseases

Frontiers in Medicine, 2022
Since the first success of interleukin-1 blockade in cryopyrin-associated periodic syndrome, the use of interleukin-1 inhibitors has expanded to other disorders, including off-label indications.
Emanuela Del Giudice, Jurgen Sota, Francesca Orlando, Ludovica Picciano, Rolando Cimaz, Luca Cantarini, Angela Mauro   +6 more
doaj   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab

Journal of Dermatological Treatment, 2023
Schnitzler syndrome (SchS) is a rare autoimmune and inflammatory disease mediated by interleukin-1 beta (IL-1β). Recurrent monoclonal gammopathy and chronic urticarial rash are the symptoms required for diagnosis according to the Strasbourg criteria. The
Angel Luis Salcedo-Mingoarranz, María Dorado-Fernández, Sofía García-Martínez, Paz Collado-Ramos, Nicolás Silvestre-Torner   +4 more
doaj   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease

Global & Regional Health Technology Assessment, 2020
Background: Anakinra, canakinumab and tocilizumab are all effective alternative treatment choice in patients with Still’s disease including both systemic juvenile idiopathic arthritis (SJIA) adult onset Still’s disease (AOSD) compared to canakinumab and ...
Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi   +2 more
doaj   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry

Rheumatology and Therapy
Introduction Interim analysis of the long-term safety and effectiveness of canakinumab, at a patient level, in the mevalonate kinase deficiency/hyperimmunoglobulin-D syndrome (MKD/HIDS) cohort of the RELIANCE registry.
Prasad T. Oommen, Tilmann Kallinich, Juergen Rech, Norbert Blank, Julia Weber-Arden, Jasmin B. Kuemmerle-Deschner   +5 more
doaj   +1 more source

Increasing the Interval of Canakinumab Administration Effectively Supports the Remission of Schnitzler’s Syndrome

Case Reports in Rheumatology, 2018
Schnitzler’s syndrome (SchS) is a rare, disabling, autoinflammatory disorder characterized by recurrent urticarial rash and monoclonal IgM gammopathy. Interleukin-1 beta (IL-1β) plays an important role in the pathophysiology of SchS.
Vadim R. Gorodetskiy, Svetlana O. Salugina, Evgeny S. Fedorov   +2 more
doaj   +1 more source